A 9,146-patient Flatiron Health study found no survival difference among palbociclib, ribociclib, and abemaciclib, so KOL influence decides prescribing share.

The largest US real-world evidence base for HR+/HER2- metastatic breast cancer runs through Flatiron Health, an electronic health record database spanning roughly 280 cancer clinics and 800 sites of care nationally, covering over 721,000 breast cancer patients. A 2025 analysis of 9,146 patients starting first-line CDK4/6 inhibitor therapy between February 2015 and November 2023 found no significant overall survival difference across palbociclib, ribociclib, and abemaciclib, with every pairwise hazard ratio sitting between 0.95 and 0.98, none statistically significant. That distributed, community-oncology-heavy evidence base looks structurally different from the concentrated academic consortia AXLRx maps elsewhere.

That equivalence finding raises the stakes on tiering influence correctly. When three drugs perform the same on survival, the prescribing decision shifts to tolerability profile, administration convenience, and which KOL a community oncologist trusts, exactly the kind of influence a tiered classification approach is built to score. No named individual enters a KOL workbook without a verification tag: every identity gets checked against live trial-registry, NCCN-panel, and publication data, then marked Verified, Industry benchmark, or Requires client validation. A commercial team that mistakes publication volume for prescribing influence in a market this size wastes MSL capacity at scale.

Publication volume is not prescribing influence, and mistaking the two wastes MSL capacity.

Five questions this report answers:

Q1 - If palbociclib, ribociclib, and abemaciclib perform equivalently, what actually drives US prescribing share?

Q2 - How is a KOL universe sized across both a small academic core and a distributed community network?

Q3 - What verification standard must every named KOL clear before entering the workbook?

Q4 - What deliverable formats come with a commissioned KOL Mapping workbook?

Q5 - How concentrated is the US KOL network driving CDK4/6 inhibitor prescribing?

Share your commercial question with us. We'll align on scope — then build the right intelligence around it.

→ moatrx.com/axlrx.html

#BreastCancer #KOLMapping #Oncology #CDK4-6Inhibitors #USMarket

Live report page:  https://axlrx.ai/breast-cancer-hr-positive-her2-negative/kol-mapping/

Thanks & Regards,

Mike || Global Pharma Commercial Marketing Head

Email-                                     hello@axlrx.ai

Web-                                     https://axlrx.ai/